Skip to content

Sleep Device Testing to Promote Sleep in Infants

Clinical Testing of a Novel Device to Promote Sleep Continuity in Infants

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05078112
Enrollment
19
Registered
2021-10-14
Start date
2021-10-20
Completion date
2022-07-31
Last updated
2024-10-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Insomnia Chronic

Brief summary

Infants often have sleep challenges. Most of these challenges in otherwise healthy children and due to behavioral insomnia. The goal for infants is to become independent sleepers by learning the process of self-soothing. This study hopes to determine if technology based on sensors is able to help teach self-soothing to infants.

Interventions

DEVICESleep sensor technology

Infants will sleep on a novel device with built-in sensor technology that tracks sleep patterns and provides output to soothe them to sleep. The device will give this output for first 10 nights, then wean the output the child receives over 10 nights.

Sponsors

Duke University
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
2 Months to 12 Months
Healthy volunteers
No

Inclusion criteria

1. Age between 2-12 months. 2. Meets clinical criteria for behavioral insomnia of childhood, sleep association subtype, as defined by the International Classification of Sleep Disorders Manual.

Exclusion criteria

1. Diagnosed comorbid health problem that may disrupt sleep. 2. History of birth prior to 37 weeks gestational age.

Design outcomes

Primary

MeasureTime frameDescription
Change in Number of Nighttime Awakenings Per Night as Measured by Parent Sleep DiaryBaseline to 5 days post-interventionParents reported number of nighttime awakenings on the 5 days immediately prior to intervention (at baseline) and 5 days immediately following the intervention. The intervention takes place during the 20 days in between the measurement of baseline measures and post-intervention measures. The number of nighttime awakenings is averaged over the 5 days prior to intervention and compared to the average over 5 days after intervention.

Secondary

MeasureTime frameDescription
Change in BISQ-SF (Brief Infant Sleep Questionnaire - Short Form) ScoreBaseline to post-intervention (approximately 20 days)The BISQ-SF is a research tool that measures infant sleep metrics, parental perceptions of the child's sleep, and parental behaviors. The total score is scaled from 0 to 100, with higher scores denoting better sleep quality, more positive perception of infant sleep, and parent behaviors that promote healthy and independent sleep.
Change in Caregiver Epworth Sleepiness Scale (ESS)Baseline to post-intervention (approximately 20 days)Caregivers evaluate their own sleepiness via the ESS. The ESS has a total score range of 0 to 24, where a higher score indicates greater sleepiness.
Change in Patient Health Questionnaire-2 (PHQ-2) ScoreBaseline to post-intervention (approximately 20 days)A PHQ-2 score ranges from 0 to 6, where a higher score indicates a greater frequency of depressed mood and anhedonia.

Countries

United States

Participant flow

Recruitment details

Participants were recruited from the Duke Pediatric outpatient clinics from October 2021 to June 2022.

Participants by arm

ArmCount
Sleep Device Intervention
Infants will utilize the sleep device during sleep for 20 days. Infants will sleep on a novel device with built-in sensor technology that tracks sleep patterns and provides output to soothe them to sleep. The device will give this output for first 10 nights, then wean the output the child receives over 10 nights.
19
Total19

Baseline characteristics

CharacteristicSleep Device Intervention
Age, Continuous6.2 months
STANDARD_DEVIATION 2.2
Ethnicity (NIH/OMB)
Hispanic or Latino
2 Participants
Ethnicity (NIH/OMB)
Not Hispanic or Latino
1 Participants
Ethnicity (NIH/OMB)
Unknown or Not Reported
16 Participants
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
Race (NIH/OMB)
Asian
0 Participants
Race (NIH/OMB)
Black or African American
2 Participants
Race (NIH/OMB)
More than one race
2 Participants
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
Race (NIH/OMB)
Unknown or Not Reported
2 Participants
Race (NIH/OMB)
White
13 Participants
Region of Enrollment
United States
19 Participants
Sex: Female, Male
Female
8 Participants
Sex: Female, Male
Male
11 Participants

Adverse events

Event typeEG000
affected / at risk
deaths
Total, all-cause mortality
0 / 19
other
Total, other adverse events
0 / 19
serious
Total, serious adverse events
0 / 19

Outcome results

Primary

Change in Number of Nighttime Awakenings Per Night as Measured by Parent Sleep Diary

Parents reported number of nighttime awakenings on the 5 days immediately prior to intervention (at baseline) and 5 days immediately following the intervention. The intervention takes place during the 20 days in between the measurement of baseline measures and post-intervention measures. The number of nighttime awakenings is averaged over the 5 days prior to intervention and compared to the average over 5 days after intervention.

Time frame: Baseline to 5 days post-intervention

ArmMeasureValue (MEAN)Dispersion
Sleep Device InterventionChange in Number of Nighttime Awakenings Per Night as Measured by Parent Sleep Diary-0.88 awakenings per nightStandard Deviation 0.89
p-value: 0.000393t-test, 2 sided
Secondary

Change in BISQ-SF (Brief Infant Sleep Questionnaire - Short Form) Score

The BISQ-SF is a research tool that measures infant sleep metrics, parental perceptions of the child's sleep, and parental behaviors. The total score is scaled from 0 to 100, with higher scores denoting better sleep quality, more positive perception of infant sleep, and parent behaviors that promote healthy and independent sleep.

Time frame: Baseline to post-intervention (approximately 20 days)

Population: Caregivers were not considered enrolled, but did contribute to this assessment. Each caregiver that had pre and post-intervention BISQ-SF scores available contributed to this assessment.

ArmMeasureValue (MEAN)Dispersion
Sleep Device InterventionChange in BISQ-SF (Brief Infant Sleep Questionnaire - Short Form) Score13.4 score on a scaleStandard Deviation 10.6
Secondary

Change in Caregiver Epworth Sleepiness Scale (ESS)

Caregivers evaluate their own sleepiness via the ESS. The ESS has a total score range of 0 to 24, where a higher score indicates greater sleepiness.

Time frame: Baseline to post-intervention (approximately 20 days)

Population: Caregivers were not considered enrolled but did contribute to this assessment. Each caregiver that had pre and post-intervention ESS scores available contributed to this assessment.

ArmMeasureValue (MEAN)Dispersion
Sleep Device InterventionChange in Caregiver Epworth Sleepiness Scale (ESS)-0.94 score on a scaleStandard Deviation 2.95
Secondary

Change in Patient Health Questionnaire-2 (PHQ-2) Score

A PHQ-2 score ranges from 0 to 6, where a higher score indicates a greater frequency of depressed mood and anhedonia.

Time frame: Baseline to post-intervention (approximately 20 days)

Population: Caregivers were not considered enrolled but did contribute to this assessment. Each caregiver that had pre and post-intervention PHQ-2 scores available contributed to this assessment.

ArmMeasureValue (MEAN)Dispersion
Sleep Device InterventionChange in Patient Health Questionnaire-2 (PHQ-2) Score-0.47 score on a scaleStandard Deviation 1.16

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026